{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:19:57Z","timestamp":1792081197687,"version":"4.4.0"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T00:00:00Z","timestamp":1238371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To extend the knowledge of course of improvement in patients with major depressive disorder (MDD), social anxiety disorder (SAD) or generalised anxiety disorder (GAD) participating in randomised placebo\u2010controlled trials (RCTs) and to infer the optimal duration of initial escitalopram treatment in clinical practice, after which intervention might be reasonable in case of non\u2010response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>\n<jats:italic>Post hoc<\/jats:italic> analysis of pooled clinical trial database for escitalopram in MDD (14 studies), GAD (4 studies) and SAD (2 studies). \u2018Onset\u2019 of action was defined as a 20% or more decrease from baseline score in disorder\u2010specific psychopathological rating scales: \u2018response\u2019 as a 50% or more decrease from baseline score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In MDD, the probability of responding at week 8 if no onset was apparent at week 2 was 43%; in patients with an onset of effect the probability was nearly 80%. Similar patterns were observed in GAD and SAD. The chance of responding beyond week 4 in MDD, GAD and SAD was 20% or less if no effect had occurred by week 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The pattern of response in these RCTs suggests that in patients with MDD, GAD or SAD in wider clinical practice, a period of at least 4\u2009weeks is worthwhile before considering further intervention. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.1019","type":"journal-article","created":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T00:04:50Z","timestamp":1238457890000},"page":"269-275","source":"Crossref","is-referenced-by-count":57,"title":["How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database"],"prefix":"10.1002","volume":"24","author":[{"given":"David S.","family":"Baldwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornah T.","family":"Dolberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borwin","family":"Bandelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,3,30]]},"reference":[{"issue":"1","key":"e_1_2_1_2_1","first-page":"97","article-title":"Fixed dose of escitalopram (10\u2009mg\/day) and a flexible dosing regimen of sertraline (50\u2013200\u2009mg\/day) in a randomised, double\u2010blind comparison in depressed patients","volume":"5","author":"Alexopoulos GS","year":"2004","journal-title":"World J Biol Psychiatry"},{"key":"e_1_2_1_3_1","first-page":"S87","article-title":"A placebo\u2010controlled trial of escitalopram and sertraline in the treatment of major depressive disorder","volume":"29","author":"Alexopoulos GS","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145705005973"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.105.012799"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000194377.88330.1d"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145701002565"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-946702"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0906"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10401230590932326"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115513"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0410"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X65484"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.10146"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1985.tb02649.x"},{"key":"e_1_2_1_16_1","volume-title":"Clinical Trials in Psychiatry","author":"Everitt BS","year":"2004"},{"key":"e_1_2_1_17_1","unstructured":"Forest Laboratories.2007a.Flexible\u2010dose comparison of the safety and efficacy of Lu 26\u2013054 (escitalopram) citalopram and placebo in the treatment major depressive disorder. Available athttp:\/\/www. forestclinicaltrials.com\/CTR\/CTRController\/CTRViewPdf?_file_id= scsr\/SCSR_SCT\u2010MD\u201002_final.pdf[Accessed 25 November 2008] (not peer\u2010reviewed)."},{"key":"e_1_2_1_18_1","unstructured":"Forest Laboratories2007b.Flexible dose comparison of the safety and efficacy of escitalopram and fluoxetine in the treatment of major depressive disorder. Available athttp:\/\/www.forestclinicaltrials.com\/CTR\/CTRController\/CTRViewPdf?_file_id=scsr\/SCSR_SCT\u2010MD\u201016_final.pdf[Accessed 25 November 2008] (not peer\u2010reviewed)."},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.11.011"},{"key":"e_1_2_1_20_1","first-page":"76","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.186.3.222"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050578"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20014"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200307000-00003"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000414022"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20222"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000078225"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1009"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.10.1500"},{"key":"e_1_2_1_32_1","unstructured":"NinanPT VenturaD WangJ.2003.Escitalopram is effective and well tolerated in the treatment of severe depression. Poster presented at the Congress of the American Psychiatric Association San Francisco CA."},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2008.02.002"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.734"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20214"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1107"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979551"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979192"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0805"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0211"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.11.1217"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199400940-00003"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200205000-00001"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.150"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(03)00053-0"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.3.469"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1019","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T22:25:01Z","timestamp":1699914301000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,30]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1002\/hup.1019"],"URL":"https:\/\/doi.org\/10.1002\/hup.1019","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,30]]}}}